《中国恶性肿瘤学科发展报告（2021）》——胃癌未来展望篇

热门医家号

换一批

Tumor公社

《Tumor公社》肿瘤医学开放式媒体平台，打造肿瘤医学领域一站式解决方案，致力于为用户公众及患者提供及时、全面的肿瘤资讯、科普知识。看百科、找医生、指南分享、搭建医生与患者、患者与患者之间的桥梁，让更多人了解肿瘤、认识肿瘤、助力健康中国2030规划纲要，推动全面科学素质普及，共建肿瘤医学科普生态圈。
caca乳腺癌科普基地
癌症防治网
耿刚教授
肿瘤好医生

专注肿瘤专家报道，专注肿瘤人文报道，全面、细致、详实的让你了解每一位肿瘤领域大咖。
CACA早筛科普基地

中国抗癌协会早癌筛查科普教育基地官方账号

Tumor公社 | 作者：中国抗癌协会 | 2022-07-12 | 0 0

30648

胃癌未来展望篇

《中国恶性肿瘤学科发展报告（2021）》——胃癌未来展望篇.png

【主编】

梁寒

【副主编】

程向东

李子禹

孙益红

王振宁

张艳桥

【编委】（按姓氏拼音排序）

刘宝瑞

金晶

张小田

【专家顾问】（审稿专家）

季加孚

徐惠绵

陈凛

沈琳

参考文献

[32] CRISTESCU R, LEE J, NEBOZHYN M et al. Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes[J]. Nature Medicine, 2015, 21(5): 449–456.

[33] CHIDA K, KAWAZOE A, KAWAZU M et al. A Low Tumor Mutational Burden and PTEN Mutations Are Predictors of a Negative Response to PD-1 Blockade in MSI-H/DMMR Gastrointestinal Tumors.[J]. Clinical Cancer Research : An Official Journal of the American Association for Cancer Research, 2021, 27(13): 3714–3724.

[34] LIU Z, WANG A, PU Y et al. Genomic and Transcriptomic Profiling of Hepatoid Adenocarcinoma of the Stomach.[J]. Oncogene, 2021, 40(38): 5705–5717.

[35] SCHOENFELD A J, HELLMANN M D. Acquired Resistance to Immune Checkpoint Inhibitors.[J]. Cancer Cell, 2020, 37(4): 443–455.

[36] MIMURA K, KUA L-F, XIAO J-F et al. Combined Inhibition of PD-1/PD-L1, Lag-3, and Tim-3 Axes Augments Antitumor Immunity in Gastric Cancer-T Cell Coculture Models.[J]. Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2021, 24(3): 611–623.

[37] OH D-Y, KANG Y-K, YAMAGUCHI K et al. MO20-2 Phase I study of BI 754091 plus BI 754111 in Asian patients with gastric/gastroesophageal junction or esophageal cancer[J/OL]. Annals of Oncology, 2021, 32: S310. https://doi.org/10.1016/j.annonc.2021.05.615.

[38] CATENACCI DVT, ROSALES MK, CHUNG HC, YOON HH, SHEN L, MOEHLER MH K Y-K. Margetuximab (M) combined with anti-PD-1 (retifanlimab) or anti-PD-1/LAG-3 (tebotelimab) +/- chemotherapy (CTX) in first-line therapy of advanced/metastatic HER2+ gastroesophageal junction (GEJ) or gastric cancer (GC)[J]. Journal of Clinical Oncology, 2021, 39(3_suppl): TPS264–TPS264.

[39] MITROUSIAS A, MAKRIS M, ZANI S et al. Laparoscopic versus Open Gastrectomy with D2 Lymph Node Dissection for Advanced Gastric Cancer: A Systematic Review.[J]. Journal of B.U.ON. : Official Journal of the Balkan Union of Oncology, 2019, 24(3): 872–882.

[40] SHIN H-J, SON S-Y, WANG B et al Long-Term Comparison of Robotic and Laparoscopic Gastrectomy for Gastric Cancer: A Propensity Score-Weighted Analysis of 2084 Consecutive Patients.[J]. Annals of Surgery, 2021, 274(1): 128–137.